NTRK1 and glioma: Thus, when feasible, pediatric LGG should be evaluated for potentially targetable alterations, as MEK1/2, BRAF, and TRK inhibitors have demonstrated promising activity in pediatric gliomas and can be considered for patients who have failed upfront chemotherapy.